Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Invested Capital (2022 - 2025)

Historic Invested Capital for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $396.6 million.

  • Immunocore Holdings' Invested Capital rose 495.91% to $396.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.6 million, marking a year-over-year increase of 495.91%. This contributed to the annual value of $360.7 million for FY2024, which is 220.34% down from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Invested Capital is $396.6 million, which was up 495.91% from $388.5 million recorded in Q2 2025.
  • Immunocore Holdings' Invested Capital's 5-year high stood at $396.6 million during Q3 2025, with a 5-year trough of $338.9 million in Q4 2022.
  • Over the past 4 years, Immunocore Holdings' median Invested Capital value was $368.8 million (recorded in 2023), while the average stood at $369.8 million.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 883.44% in 2023, then plummeted by 220.34% in 2024.
  • Over the past 4 years, Immunocore Holdings' Invested Capital (Quarter) stood at $338.9 million in 2022, then grew by 8.83% to $368.8 million in 2023, then dropped by 2.2% to $360.7 million in 2024, then increased by 9.94% to $396.6 million in 2025.
  • Its last three reported values are $396.6 million in Q3 2025, $388.5 million for Q2 2025, and $378.5 million during Q1 2025.